open access

Vol 61, No 5 (2010)
Original papers
Published online: 2010-11-04
Submitted: 2013-02-15
Get Citation

Urinary iodine in patients with differentiated thyroid cancer (DTC) during L-thyroxine treatment

Barbara Michalik, Józef Roskosz, Anita Stanjek-Cichoracka, Jolanta Krajewska, Michał Kalemba, Aleksandra Kochańska-Dziurowicz, Barbara Jarząb
Endokrynologia Polska 2010;61(5):458-461.

open access

Vol 61, No 5 (2010)
Original papers
Published online: 2010-11-04
Submitted: 2013-02-15

Abstract


Introduction: Urinary iodine concentrations were analyzed in the morning urine samples of patients with differentiated thyroid cancer (DTC).
Material and methods: The analyzed group included 572 DTC patients who were treated with radioiodine or hospitalized for evaluation of radioiodine treatment effects in 2009 at the Institute of Oncology in Gliwice. Ioduria was analyzed by PAMM (Program Against Micronutrient Malnutrition) method before rhTSH administration. A total of 545 tests were performed during L-thyroxine treatment and 27 after L-thyroxine withdrawal.
Results: Median L-thyroxine dose was 150 μg/day. Median ioduria was 127.5 μg/L during L-thyroxine therapy and 134 μg/L after the L-thyroxine withdrawal. No distinct relation between ioduria and L-thyroxine dose was observed. Ioduria < 200 μg/L was observed in over 90% of patients and this cut-off was chosen for the reference range. Only 1.2% of patients showed a distinct stable iodine contamination (ioduria ≥ 300 μg/L).
Conclusions: Urinary iodine concentrations in differentiated thyroid cancer patients treated with L-thyroxine vary in a wide range and do not show a clear relation with L-thyroxine dose.
(Pol J Endocrinol 2010; 61 (5): 458-461)

Abstract


Introduction: Urinary iodine concentrations were analyzed in the morning urine samples of patients with differentiated thyroid cancer (DTC).
Material and methods: The analyzed group included 572 DTC patients who were treated with radioiodine or hospitalized for evaluation of radioiodine treatment effects in 2009 at the Institute of Oncology in Gliwice. Ioduria was analyzed by PAMM (Program Against Micronutrient Malnutrition) method before rhTSH administration. A total of 545 tests were performed during L-thyroxine treatment and 27 after L-thyroxine withdrawal.
Results: Median L-thyroxine dose was 150 μg/day. Median ioduria was 127.5 μg/L during L-thyroxine therapy and 134 μg/L after the L-thyroxine withdrawal. No distinct relation between ioduria and L-thyroxine dose was observed. Ioduria < 200 μg/L was observed in over 90% of patients and this cut-off was chosen for the reference range. Only 1.2% of patients showed a distinct stable iodine contamination (ioduria ≥ 300 μg/L).
Conclusions: Urinary iodine concentrations in differentiated thyroid cancer patients treated with L-thyroxine vary in a wide range and do not show a clear relation with L-thyroxine dose.
(Pol J Endocrinol 2010; 61 (5): 458-461)
Get Citation

Keywords

thyroid cancer; ioduria; L-thyroxine treatment

About this article
Title

Urinary iodine in patients with differentiated thyroid cancer (DTC) during L-thyroxine treatment

Journal

Endokrynologia Polska

Issue

Vol 61, No 5 (2010)

Pages

458-461

Published online

2010-11-04

Bibliographic record

Endokrynologia Polska 2010;61(5):458-461.

Keywords

thyroid cancer
ioduria
L-thyroxine treatment

Authors

Barbara Michalik
Józef Roskosz
Anita Stanjek-Cichoracka
Jolanta Krajewska
Michał Kalemba
Aleksandra Kochańska-Dziurowicz
Barbara Jarząb

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl